The FDA is generally not persuaded by post-hoc analysis of a failed clinical trial. This might be an exception, however, because OCRX's new explanation for what went wrong is quite plausible.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.